127 related articles for article (PubMed ID: 37652236)
1. Liposome-encapsulated zoledronate increases inflammatory macrophage population in TNBC tumours.
Petruk N; Sousa S; Croset M; Polari L; Zlatev H; Selander K; Mönkkönen J; Clézardin P; Määttä J
Eur J Pharm Sci; 2023 Nov; 190():106571. PubMed ID: 37652236
[TBL] [Abstract][Full Text] [Related]
2. Liposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cells.
Sousa S; Auriola S; Mönkkönen J; Määttä J
BMC Cancer; 2015 Jan; 15():4. PubMed ID: 25588705
[TBL] [Abstract][Full Text] [Related]
3. CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases.
Petruk N; Siddiqui A; Tadayon S; Määttä J; Mattila PK; Jukkola A; Sandholm J; Selander KS
Front Immunol; 2023; 14():1179022. PubMed ID: 37533856
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
[TBL] [Abstract][Full Text] [Related]
5. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
[TBL] [Abstract][Full Text] [Related]
6. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
[TBL] [Abstract][Full Text] [Related]
7. Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model.
Zhang Q; Le K; Xu M; Zhou J; Xiao Y; Yang W; Jiang Y; Xi Z; Huang T
Int Immunopharmacol; 2019 Nov; 76():105864. PubMed ID: 31480004
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of antitumor effect of zoledronic acid entrapped in folate-linked liposome for targeting to tumor-associated macrophages.
Hattori Y; Yamashita J; Sakaida C; Kawano K; Yonemochi E
J Liposome Res; 2015; 25(2):131-40. PubMed ID: 25203609
[TBL] [Abstract][Full Text] [Related]
9. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer.
Steenbrugge J; Breyne K; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Colpaert C; Vermeulen P; Van Laere S; Meyer E
J Exp Clin Cancer Res; 2018 Aug; 37(1):191. PubMed ID: 30111338
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of an innovative anti-TAM approach based on zoledronate-loaded erythrocytes.
Sabatino R; Battistelli S; Magnani M; Rossi L
Drug Deliv Transl Res; 2018 Oct; 8(5):1355-1364. PubMed ID: 30014237
[TBL] [Abstract][Full Text] [Related]
12. The combined use of Camellia sinensis and metronomic zoledronate in 4T1 mouse carcinoma against tumor growth and metastasis.
Luo KW; Yue GG; Ko CH; Gao S; Lee JK; Li G; Fung KP; Leung PC; Lau CB
Oncol Rep; 2015 Jul; 34(1):477-87. PubMed ID: 25998578
[TBL] [Abstract][Full Text] [Related]
13. Intravascular Administration of Acridine Orange and Zoledronate in a Bone Metastasis Model of Breast Cancer.
Shoji R; Tsuchie H; Nagasawa H; Hongo M; Kasukawa Y; Nozaka K; Kudo D; Saito H; Abe K; Igarashi S; Harata S; Kasama F; Miyakoshi N
Anticancer Res; 2022 Nov; 42(11):5357-5363. PubMed ID: 36288846
[TBL] [Abstract][Full Text] [Related]
14. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model.
Hung TT; Chan J; Russell PJ; Power CA
PLoS One; 2011; 6(5):e19389. PubMed ID: 21603655
[TBL] [Abstract][Full Text] [Related]
16. Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.
Sun L; Li Y; Jiang Z; Zhang J; Li H; Li B; Ye Z
Tumour Biol; 2016 Jun; 37(6):7333-44. PubMed ID: 26676633
[TBL] [Abstract][Full Text] [Related]
17. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
[TBL] [Abstract][Full Text] [Related]
18. Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis from triple negative breast cancer by simultaneously killing cancer cells and reprogramming the microenvironment of bone resorption and immunosuppression.
Liu B; Yang Q; Cheng Y; Liu M; Ji Q; Zhang B; Yang Z; Zhou S; Liu D
Acta Biomater; 2023 Aug; 166():640-654. PubMed ID: 37236576
[TBL] [Abstract][Full Text] [Related]
19. CCN1, a candidate target for zoledronic acid treatment in breast cancer.
Espinoza I; Liu H; Busby R; Lupu R
Mol Cancer Ther; 2011 May; 10(5):732-41. PubMed ID: 21393426
[TBL] [Abstract][Full Text] [Related]
20. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.
Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A
J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
